These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 24471316)

  • 1. [Discussion about relativity between post-marketed safety outcome and treatment course of traditional Chinese medicine drugs on basis of reinforced urn processes].
    Zhong CL; Hu SY; Xie YM; Wang YY
    Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2983-6. PubMed ID: 24471316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Exploration of how to formulate guidelines on post-marketing traditional Chinese medicine surveillance].
    Zhang W; Xie YM; Yu WY
    Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2943-8. PubMed ID: 24471309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Phase 0 clinical trials and post-marketed re-evaluation of clinical safety in injection of traditional Chinese medicine].
    Wei X; Zhang Z; Xie Y; Wang Y
    Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2874-6. PubMed ID: 22292389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A discussion of key issues on postmarketing reevaluation of Chinese medicine].
    Xie Y; Tian F
    Zhongguo Zhong Yao Za Zhi; 2010 Jun; 35(11):1494-7. PubMed ID: 20822029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Necessity of applying pharmacovigilance in post-marketing safety monitoring of traditional Chinese medicine injections].
    Wang HN; Chen W; Fu Z; Du WM; He J
    Zhongguo Zhong Yao Za Zhi; 2008 Mar; 33(5):612-4. PubMed ID: 18536393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Significance of re-evaluation and development of Chinese herbal drugs].
    Gao Y; Ma Z; Zhang B
    Zhongguo Zhong Yao Za Zhi; 2012 Jan; 37(1):1-4. PubMed ID: 22741451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A SAS macro for target dose estimation by reinforced urn processes in phase I clinical trials.
    Zhong C; Zhuo Y; Xia J; Hu S; Li C; Jiang Z; Wang S
    Comput Methods Programs Biomed; 2011 Mar; 101(3):282-96. PubMed ID: 21329999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Development of quality traceability system of traditional Chinese medicine].
    Cai Y; Hu H; Ni JY; Wang YT
    Zhongguo Zhong Yao Za Zhi; 2013 Nov; 38(22):3829-33. PubMed ID: 24558859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Design requirements for clinical trials on re-evaluation of safety and efficacy of post-marketed Chinese herbs].
    Xie Y; Wei X
    Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2768-70. PubMed ID: 22292360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Discussion on methods of sample size estimation in conducting clinical reevaluation of postmarketing Chinese medicine].
    Tian F; Fu Y; Xie Y
    Zhongguo Zhong Yao Za Zhi; 2011 Apr; 36(8):1097-102. PubMed ID: 21809593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Establishment of model of traditional Chinese medicine injections post-marketing safety monitoring].
    Guo XE; Zhao YB; Xie YM; Zhao LC; Li YF; Hao Z
    Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2974-8. PubMed ID: 24471314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical outcomes research of traditional Chinese medicine--introduce registry intensive hospital monitoring study protocol of traditiona Chinese medicine injection's safety].
    Yang W; Xie YM; Wang YY
    Zhongguo Zhong Yao Za Zhi; 2012 Sep; 37(18):2683-5. PubMed ID: 23285907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Safety evaluation of traditional Chinese medicine injections and study of related key technology].
    Cheng F; Liu Z
    Zhongguo Zhong Yao Za Zhi; 2009 Apr; 34(8):1052-4. PubMed ID: 19639795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical orientation of post-marketing Chinese patent drugs: an evidence-based practice].
    Shang HC; Zhang BL; Li YP
    Zhong Xi Yi Jie He Xue Bao; 2008 Sep; 6(9):887-90. PubMed ID: 18782528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Research on establishment of clinical safety intensive hospital monitoring net of traditional Chinese medicine injection].
    Wang LX; Xie YM; Wang ZF
    Zhongguo Zhong Yao Za Zhi; 2012 Sep; 37(18):2692-4. PubMed ID: 23285910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Interpretation and analysis of traditional Chinese medicine injection instructions].
    Liu MY; Jiao LH; Xie YM; Wang GW; Zheng Q
    Zhongguo Zhong Yao Za Zhi; 2012 Sep; 37(18):2707-9. PubMed ID: 23285915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Influencing factor and mechanism analysis of adverse drug reaction in traditional Chinese medicine injection].
    Wei X; Xie YM
    Zhongguo Zhong Yao Za Zhi; 2012 Sep; 37(18):2748-51. PubMed ID: 23285926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Interpretation of contemporary positioning of traditional Chinese medicine injections and analysis of key problems].
    Gao F; Leng J; Fu CM; Zhang JM; Liao W; Hu HL; He Y; Gan YX; Hao L
    Zhongguo Zhong Yao Za Zhi; 2014 Sep; 39(17):3416-9. PubMed ID: 25522642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Postmarketing herbs clinical evaluation should concern about re-evaluating symptoms].
    He W; Xie Y; Wang Y
    Zhongguo Zhong Yao Za Zhi; 2010 Jun; 35(11):1498-500. PubMed ID: 20822030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical orientation and thought on several problems in post-marketed reassessment of traditional Chinese medicine].
    Wang X; Su X; Yu J; Xie Y; Wang Y
    Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2893-7. PubMed ID: 22292394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.